Medical Device News Magazine

Argonne Uncovers Insights About Prostate Cancer Risk and Genetic Ancestry

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Reports Study

A recent study involving scientists from the U.S. Department of Energy’s (DOE) Argonne National Laboratory has uncovered insights into the prostate cancer risks of people from a variety of genetic ancestries. The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs (VA) and DOE.

The truly unique factor of this research was the data provided by the MVP. The MVP is one of the largest and most diverse collections of genetic information in the world, with one million veterans joining since the program’s launch in 2011. The study of this genetic data was performed using the latest techniques in high performance computing (HPC) and artificial intelligence (AI), and this unprecedented biobank enabled researchers to reach further than any that came before it.

Studying Populations

Prostate cancer is the most frequently diagnosed non-skin cancer globally, and as such, it is a problem that affects the entire human population. To understand the likelihood of an individual or population developing prostate cancer, researchers create what is known as a Genetic Risk Score (GRS). This is an estimate of the cumulative contribution of genetic factors to a specific health outcome.

Specifically, the research group focused on single nucleotide polymorphisms (SNPs.) These are variations at a single position in a DNA sequence that act as biological markers that help scientists locate genes that are associated with disease.

For this study of 156,319 prostate cancer cases and 788,443 control cases, the GRS is calibrated by adding up all the risks contributed by individual SNPs. Here, the researchers found 187 new genetic markers that provide more accuracy in calculating the risk posed by a particular ancestry. This increased the total number of known risk variants to 451.

Different ancestries, different risks

This work was centered around a desire to understand the genetic makeup that increases risks for diseases like prostate cancer. Of course, genetic architecture is heavily based on a person’s ancestry, and previous studies did not include people who do not share a European ancestry.

This is especially true of people with African ancestry. In this study, the case sample size was increased by 43% for people of European ancestry over previous studies, 26% for those with Asian ancestry, 45% for Hispanic groups and a whopping 87% for those with African ancestry.

The increase of representation is obviously important for groups that are often marginalized and forgotten, but it also helps people outside of these groups.

Science involving such a large database like MVP can sometimes feel impersonal, as the individual can often be lost in such a large group. But the contributions of every person involved is of the utmost importance — not only for what they contribute to science with their data, but also in terms of what they’ve provided for their country.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”